Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ASL
Argentum Silver
C$0.05
-16.7%
C$0.06
C$0.03
C$0.09
C$2.58M1.9413,401 shs100,800 shs
BELLUS Health Inc. stock logo
BLU
BELLUS Health
$14.74
$14.62
$6.38
$14.76
$1.87B0.193.08 million shs3.45 million shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ASL
Argentum Silver
0.00%-16.67%-16.67%-33.33%+66.67%
BELLUS Health Inc. stock logo
BLU
BELLUS Health
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ASL
Argentum Silver
N/AN/AN/AN/AN/AN/AN/AN/A
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ASL
Argentum Silver
0.00
N/AN/AN/A
BELLUS Health Inc. stock logo
BLU
BELLUS Health
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ASL
Argentum Silver
N/AN/AC$0.02 per share3.16N/AN/A
BELLUS Health Inc. stock logo
BLU
BELLUS Health
$15K124,613.93N/AN/A$3.09 per share4.77
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ASL
Argentum Silver
N/AN/AN/AN/AN/A-89.19%-46.32%N/A
BELLUS Health Inc. stock logo
BLU
BELLUS Health
-$76.08M-$0.72N/AN/AN/A-578,586.63%-24.27%-23.14%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ASL
Argentum Silver
N/AN/AN/AN/AN/A
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ASL
Argentum Silver
N/A
4.65
14.02
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/A
33.42
33.42

Institutional Ownership

CompanyInstitutional Ownership
ASL
Argentum Silver
N/A
BELLUS Health Inc. stock logo
BLU
BELLUS Health
90.37%

Insider Ownership

CompanyInsider Ownership
ASL
Argentum Silver
62.18%
BELLUS Health Inc. stock logo
BLU
BELLUS Health
24.17%
CompanyEmployeesShares OutstandingFree FloatOptionable
ASL
Argentum Silver
N/A51.60 millionN/ANot Optionable
BELLUS Health Inc. stock logo
BLU
BELLUS Health
74126.81 million96.16 millionNot Optionable

Recent News About These Companies

City Beer Hall unveils new ‘Blu Pizza’ pop-up

Argentum Silver CVE:ASL

C$0.05 -0.01 (-16.67%)
As of 07/3/2025 11:08 AM Eastern

Argentum Silver Corp., a junior mineral exploration company, engages in the acquisition, exploration, evaluation, and development of mineral properties in Canada and Peru. It holds 100% interest in the Cochavara silver-lead-zinc project comprising six concessions covering an area of approximately 3,479 hectares located in La Libertad, northern Peru. The company was formerly known as Silex Ventures Ltd. and changed its name to Argentum Silver Corp. in February 2011. Argentum Silver Corp. was incorporated in 2007 and is headquartered in Toronto, Canada. Argentum Silver Corp. operates as a subsidiary of Sprott Mining Inc.

BELLUS Health stock logo

BELLUS Health NASDAQ:BLU

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.